Navellier & Associates Inc Horizon Therapeutics Public LTD CO Transaction History

Navellier & Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$79.4 - $116.36 $55,500 - $81,335	-699 Reduced 2.63%	25,916 $2.07 Million
Q1 2022 Apr 29, 2022	SELL	$86.42 - $109.81 $897,990 - $1.14 Million	-10,391 Reduced 28.08%	26,615 $2.8 Million
Q4 2021 Feb 14, 2022	BUY	$98.56 - $119.91 $73,821 - $89,812	749 Added 2.07%	37,006 $3.99 Million
Q3 2021 Oct 28, 2021	BUY	$91.91 - $110.37 $90,807 - $109,045	988 Added 2.8%	36,257 $3.97 Million
Q2 2021 Aug 09, 2021	BUY	$86.24 - $95.92 $76,926 - $85,560	892 Added 2.59%	35,269 $3.3 Million
Q1 2021 May 12, 2021	SELL	$71.83 - $95.48 $31,389 - $41,724	-437 Reduced 1.26%	34,377 $3.16 Million
Q4 2020 Feb 05, 2021	BUY	$67.0 - $84.39 $331,918 - $418,068	4,954 Added 16.59%	34,814 $2.55 Million
Q3 2020 Nov 09, 2020	BUY	$55.23 - $79.93 $1.65 Million - $2.39 Million	29,860 New	29,860 $2.32 Million

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.